Document is current
Any future updates will be listed below
-
Authors
Andreatta, Massimo http://orcid.org/0000-0002-8036-2647
Corria-Osorio, Jesus
Müller, Sören http://orcid.org/0000-0001-9490-5270
Cubas, Rafael
Coukos, George http://orcid.org/0000-0001-8813-7367
Carmona, Santiago J. http://orcid.org/0000-0002-2495-0671
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (180010)
- License Information
-
More Information
Article History
Received: 5 October 2020
Accepted: 22 April 2021
First Online: 20 May 2021
Competing interests
: MA, JCO, SJC declare no competing interests. GC has received grants, research support or is coinvestigator in clinical trials by BMS, Celgene, Boehringer Ingelheim, Roche, Iovance, and Kite; has received honoraria for consultations or presentations by Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure, and GeneosTx; he has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T-cell expansion and engineering for T-cell therapy; and he receives royalties from the University of Pennsylvania for CAR-T technologies licensed to Novartis. SM and RC are employees of Genentech, Inc, a member of the Roche family and receive salary and stock from Roche.
